 | • レポートコード：MRC2203A158 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界の無細胞タンパク質発現市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（付属品・消耗品、ライセートシステム）分析、用途別（酵素エンジニアリング、ハイスループット生産、タンパク質標識、タンパク質間相互作用、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の無細胞タンパク質発現市場規模：製品別（付属品・消耗品、ライセートシステム） ・世界の無細胞タンパク質発現市場規模：用途別（酵素エンジニアリング、ハイスループット生産、タンパク質標識、タンパク質間相互作用、その他） ・世界の無細胞タンパク質発現市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Biotechrabbit GmbH、CellFree Sciences Co. Ltd、Cube Biotech GmbH、…） ・市場機会・将来傾向 |
The cell-free protein expression market is expected to register a CAGR of nearly 6.1%, during the forecast period, 2019-2024.
Key Highlights
- The major factors for the growth of the cell-free protein expression market include the increasing R&D in the fields of proteomics and genomics, high prevalence of cancer and infectious diseases, and shorter-expression time and structural modification.
- Cell-free protein expression employs cell lysates to produce the desired recombinant proteins. The primary advantage of this technique is the aversion of workflow hurdles of maintaining cell culture or living cells. Cell lysates are produced by the breakdown and use of cellular components of eukaryotic or bacterial cells. Currently, several cell-free protein expression systems are commercially available, based on E. coli, rabbit reticulocytes, wheat germs, human cell lines, and insect cells.
- An in vitro protein expression system has significant advantages over living cell-based protein expression, including a shorter duration of the process, isotopic labeling of proteins, incorporation of non-natural amino acids, and optimization of protein complexes.
- The ability to enable high throughput production, pertaining to the recent trend of more research in personalized medicine and growing needs for biological therapies for the management of cancer, is a major driver for the adoption of cell-free protein expression techniques, by pharmaceutical and biotechnology firms.
Key Market Trends
The E. Coli Lysate Segment of the Lysate Systems is Expected to be the Fastest Growing Segment Over the Forecast Period
E. coli lysates are the most commonly used systems among all available commercial lysate systems. E. coli lysates are devoid of endogenous genetic messages and have advantages, such as very high protein yield and tolerability to most additives. Furthermore, E. coli-based systems are being used in recombinant techniques for the manufacture of various biological therapeutics and insulin. Continuous use has enabled research on interactions and tolerability of the byproducts of E. coli-based systems, and significant present scientific literature enables its rapid adoption by industries and academics.
In E. coli-based systems, codons used are different, with some being eukaryotic specific. Additionally, post-translational modifications are not possible, which in turn, limit the system’s usage in the synthesis of specific human therapeutics. Significant advancements have been, however, made in order to address these problems. Therefore, the E. coli lysate sub-segment is expected to register a steady growth rate during the forecast period, owing to high adoption rates and recent developments.
North America is Expected to Dominate the Market
North America is found to hold a major share in the cell-free protein expression market, and it is expected to show a similar trend over the forecast period, without significant fluctuations. The primary factors behind the large market size include the increasing prevalence of chronic diseases, such as cancer, aging population, growing demand for targeted and personalized medicine, the presence of major R&D facilities, and favorable government initiatives in the United States. There is a growing trend of cell-based research in the US academia and biotechnology industries. In recent years, several government initiatives have been supplementing the growth of the cell-free protein expression market in the United States.
For instance, 2015 saw the introduction of the Precision Medicine Initiative in the United States, which was intended to revolutionize the treatment of many chronic diseases, including cancer. Initiatives like these are presenting a favorable environment for pharmaceutical and biotechnology firms to develop and market protein-based therapeutics, thus, fueling the growth of the cell-free protein expression market.
Competitive Landscape
The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some of the market players are biotechrabbit GmbH, CellFree Sciences Co. Ltd, Cube Biotech GmbH, GeneCopoeia Inc., Jena Bioscience GmbH, Promega Corporation, Qiagen NV, Sigma-Aldrich Corporation (Merck KGaA), Takara Bio Inc., and Thermo Fisher Scientific Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D in the Fields of Proteomics and Genomics
4.2.2 Growing Burden of Cancer and Infectious Diseases
4.2.3 Shorter Expression Time and Structural Modification
4.3 Market Restraints
4.3.1 High Cost of Protein Expression Systems
4.3.2 Lack of Effective Systems for Post-translational Modifications
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Products
5.1.1 Accessories and Consumables
5.1.2 Lysate Systems
5.1.2.1 E. Coli Lysate
5.1.2.2 Wheat Germ Extract Lysate
5.1.2.3 Rabbit Reticulocyte Lysate
5.1.2.4 Insect Cell Lysate
5.1.2.5 Human Cell Lysate
5.1.2.6 Other Lysate Systems
5.2 By Application
5.2.1 Enzyme Engineering
5.2.2 High Throughput Production
5.2.3 Protein Labeling
5.2.4 Protein-Protein Interaction
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biotechrabbit GmbH
6.1.2 CellFree Sciences Co. Ltd
6.1.3 Cube Biotech GmbH
6.1.4 GeneCopoeia Inc.
6.1.5 Jena Bioscience GmbH
6.1.6 Promega Corporation
6.1.7 Creative Biolabs
6.1.8 Merck KGaA
6.1.9 Takara Bio Inc.
6.1.10 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS